DexCom, Inc. vs Abbvie Inc.
DXCM vs ABBV — side-by-side comparison from reported financials. DXCM leads 8, ABBV leads 3 of 11 comparable metrics.
DexCom, Inc.
DXCM · Healthcare
$84.11-0.36%Strong
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | DXCM | ABBV |
|---|---|---|
| Price | $84.11 | $276.43 |
| Market cap | $31.7B | $488B |
| Revenue (TTM) | $4.97B | $64.4B |
| Revenue growth | +17.0% | +1.8% |
| Net margin | 20.1% | 9.8% |
| Free cash flow | $1.41B | $18.2B |
| Net cash (debt) | ($479M) | ($56.2B) |
| 1-year price return | +23.5% | +19.8% |
| P/E | 31.7 | 77.4 |
| P/E vs own history (cheap-side %) | 93% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | 36% | 96% |
| Altman Z-score | 6.78 | 2.33 |
| CV checks passed | 10 of 10 | 9 of 10 |
| Employees | 11,100 | 57,000 |
Full résumé-style profiles: DXCM CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.